Tech Company Financing Transactions
Vetigenics Funding Round
Private investors participated in a $6 million Seed funding round for Vetigenics. The round was announced on 2/3/2025.
Transaction Overview
Company Name
Announced On
2/3/2025
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance clinical-stage programs toward pivotal trials, accelerate preclinical candidates, and scale up operations and manufacturing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Cira Center, 2929 Arch St. 4th Floor
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Undisclosed
Website
Email Address
Overview
Our Mission: Devoted to developing antibody-based therapies that allow pets with chronic diseases to thrive, not just survive. Vetigenics is a pet health biopharma company devoted to enabling pets to live their best lives. Vetigenics was established in 2017 to address the growing need within the National Cancer Institute (NCI) to generate fully canine research antibodies to treat dogs with cancer, as a parallel patient population to inform cancer treatments for humans.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adriann Sax
Browse more venture capital transactions:
Prev: 2/3/2025: Jump venture capital transaction
Next: 2/3/2025: Myne venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs